For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

The researchers reported that tirzepatide (0% to 40.6%) and semaglutide 2.4 mg (0% to 32.2%) increased significantly among adults without diabetes with any or incident use of WLMs, though ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

This study included 10,193 individuals who initiated tirzepatide without a T2D diagnosis, of whom 3470 had a 6-month post-index follow-up and were included in the AOM-eligible cohort.

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Tirzepatide was first approved for use in the US in May 2022, when it received an indication for adult patients with type 2 diabetes. 1 Indications for chronic weight management and sleep apnea ...